{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:40:17Z","timestamp":1766580017057},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>Enthesitis is a hallmark feature of the spondyloarthropathies (SpA). This review provides an overview of recent insights on diagnosis and management of enthesitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>Recent studies support the use of imaging for diagnosis because of its higher sensitivity and specificity compared with clinical examination. Several new MRI and ultrasound scoring systems have been developed for enthesitis, which may facilitate the use of imaging in research. Enthesitis has been evaluated as a primary study outcome mainly in psoriatic arthritis (PsA); however, the use of different indices and definitions of improvement limits comparison across studies. There is very limited information about the efficacy of synthetic disease modifying antirheumatic drugs (DMARDs) for the treatment of enthesitis. In contrast, targeted and biologic DMARDs have all shown efficacy in treating enthesitis compared with placebo. There have been only a few head-to-head trials that compared two different cytokine inhibitors for the treatment of enthesitis. Preliminary data suggest that targeting IL-17 or IL12\/23 may be more efficacious for controlling enthesitis than TNF inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Emerging data suggest interleukin-17 and 12\/23 inhibitors may be the first choice in PsA patients with enthesitis. Further head-to-head studies are needed before making definitive recommendations.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000715","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T08:21:38Z","timestamp":1589530898000},"page":"380-386","source":"Crossref","is-referenced-by-count":6,"title":["The management of enthesitis in clinical practice"],"prefix":"10.1097","volume":"32","author":[{"given":"Sahil","family":"Koppikar","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Women's College Hospital"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Women's College Hospital"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/acr.23174","article-title":"Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus nonradiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/acr.23249","article-title":"Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"69","author":"Mease","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2019.06.016","article-title":"Psoriasis is an independent risk factor for entheseal damage in axial spondyloarthritis","volume":"50","author":"Solmaz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R6-20230828","first-page":"299","article-title":"Greater magnitude of entheseal microdamage and repair in psoriatic arthritis compared with ankylosing spondylitis on ultrasound","volume":"58","author":"Arslan Alhussain","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.171094","article-title":"Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00296-019-04480-9","article-title":"Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multicenter study","volume":"40","author":"Sunar","year":"2019","journal-title":"Rheumatol Int"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3899\/jrheum.181331","article-title":"Peripheral manifestations in spondyloarthritis and their effect: an ancillary analysis of the ASAS-COMOSPA Study","volume":"47","author":"Lopez-Medina","year":"2019","journal-title":"J Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3899\/jrheum.171406","article-title":"Influence of disease manifestations on health-related quality of life in early psoriatic arthritis","volume":"45","author":"Wervers","year":"2018","journal-title":"J Rheumatol"},{"issue":"(Suppl 1)","key":"R11-20230828","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.160387","article-title":"Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab","volume":"44","author":"Mease","year":"2017","journal-title":"J Rheumatol"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s42358-019-0066-8","article-title":"Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI","volume":"59","author":"Palominos","year":"2019","journal-title":"Adv Rheumatol"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32098\/mltj.02.2016.12","article-title":"Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound","volume":"6","author":"Kristensen","year":"2016","journal-title":"Muscles Ligaments Tendons J"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.171411","article-title":"Ultrasonographic and clinical assessment of peripheral enthesitis in patients with psoriatic arthritis, psoriasis, and fibromyalgia syndrome: the ULISSE Study","volume":"46","author":"Macchioni","year":"2019","journal-title":"J Rheumatol"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00296-016-3562-8","article-title":"An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment","volume":"36","author":"Perrotta","year":"2016","journal-title":"Rheumatol Int"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/rheumatology\/ker284","article-title":"Clinical and ultrasonography assessment of peripheral enthesitis in ankylosing spondylitis","volume":"50","author":"Spadaro","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","article-title":"MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group","volume":"78","author":"Maksymowych","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/bonekey.2015.124","article-title":"Treatment of bone marrow lesions (bone marrow edema)","volume":"4","author":"Eriksen","year":"2015","journal-title":"Bonekey Rep"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3899\/jrheum.181093","article-title":"The OMERACT MRI in enthesitis initiative: definitions of key pathologies, suggested MRI Sequences, and a Novel Heel Enthesitis Scoring System","volume":"46","author":"Mathew","year":"2019","journal-title":"J Rheumatol"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3899\/jrheum.181084","article-title":"Development and validation of an OMERACT MRI whole-body score for inflammation in peripheral joints and entheses in inflammatory arthritis (MRI-WIPE)","volume":"46","author":"Krabbe","year":"2019","journal-title":"J Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative","volume":"77","author":"Balint","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3899\/jrheum.171465","article-title":"Development of a preliminary ultrasonographic enthesitis score in psoriatic arthritis - GRAPPA Ultrasound Working Group","volume":"46","author":"Tom","year":"2019","journal-title":"J Rheumatol"},{"key":"R24-20230828","article-title":"Imaging techniques: options for the diagnosis and monitoring of treatment of enthesitis in psoriatic arthritis","author":"Bakewell","year":"2019","journal-title":"J Rheumatol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3899\/jrheum.171466","article-title":"Psoriatic arthritis sonographic enthesitis instruments: a systematic review of the literature","volume":"46","author":"Elalouf","year":"2019","journal-title":"J Rheumatol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.180856","article-title":"Peritenon extensor tendon inflammation in psoriatic arthritis is an enthesitis-related lesion","volume":"46","author":"Macia-Villa","year":"2019","journal-title":"J Rheumatol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/ard.2010.147272","article-title":"Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level","volume":"70","author":"Gutierrez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R28-20230828","first-page":"459","article-title":"Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands","volume":"34","author":"Zabotti","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-019-04445-0","article-title":"Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years","volume":"38","author":"Elnady","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R30-20230828","first-page":"593","article-title":"Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement","volume":"37","author":"Zuliani","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate efficacy in the tight control in Psoriatic Arthritis Study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s10067-006-0460-6","article-title":"The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases","volume":"26","author":"Genc","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"e000669","DOI":"10.1136\/rmdopen-2018-000669","article-title":"Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies","volume":"4","author":"Gladman","year":"2018","journal-title":"RMD Open"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","article-title":"Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3899\/jrheum.100069","article-title":"Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study","volume":"37","author":"Gladman","year":"2010","journal-title":"J Rheumatol"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: posthoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"e000990","DOI":"10.1136\/rmdopen-2019-000990","article-title":"Efficacy of ustekinumab in biologic-naive patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2","volume":"5","author":"McInnes","year":"2019","journal-title":"RMD Open"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10067-017-3953-6","article-title":"Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study","volume":"37","author":"Chimenti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis ((T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R55-20230828","first-page":"30263","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomized, placebo-controlled phase 3 trial","volume":"495","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"R56-20230828","article-title":"Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients","author":"Orbai","year":"2019","journal-title":"J Rheumatol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3899\/jrheum.180797","article-title":"Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and metaanalysis","volume":"47","author":"Mourad","year":"2020","journal-title":"J Rheumatol"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T03:52:47Z","timestamp":1696132367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000715","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}